Neoadjuvant Therapy in Oesophageal Cancer- An International Standard of Care

Despite low postoperative mortality rates, the long-term outcomes from surgical-based treatment for oesophageal cancer remain poor. Neoadjuvant (NA) Chemoradiotherapy (CRT) or chemotherapy has both been used to improve these outcomes. The optimal NA approach is yet to be defined through high quality evidence and remains the preference of individual clinicians. The evidence for neoadjuvant treatment is stronger and based on the current evidence NA CRT can be recommended as a treatment approach in oesophageal cancer for both adenocarcinoma and squamous cell carcinoma, but further work is needed to establish its superiority over NA chemotherapy alone, particularly for adenocarcinoma.